Jazz Pharmaceuticals
JAZZ
355 hedge funds and large institutions have $9.07B invested in Jazz Pharmaceuticals in 2015 Q1 according to their latest regulatory filings, with 54 funds opening new positions, 137 increasing their positions, 123 reducing their positions, and 52 closing their positions.
20% more funds holding in top 10
Funds holding in top 10: 15 → 18 (+3)
11% more repeat investments, than reductions
Existing positions increased: 137 | Existing positions reduced: 123
4% more first-time investments, than exits
New positions opened: 54 | Existing positions closed: 52
2% more capital invested
Capital invested by funds: $8.93B → $9.07B (+$141M)
1% less funds holding
Funds holding: 358 → 355 (-3)
40% less call options, than puts
Call options by funds: $58M | Put options by funds: $97.3M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Bank of New York Mellon
New York
|
+$97.6M |
| 2 |
PHS
PFM Health Sciences
San Francisco,
California
|
+$90.1M |
| 3 |
Westfield Capital Management
Boston,
Massachusetts
|
+$68.5M |
| 4 |
PI
Putnam Investments
Boston,
Massachusetts
|
+$58.9M |
| 5 |
HM
HealthCor Management
New York
|
+$55.8M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
LPC
Lone Pine Capital
Greenwich,
Connecticut
|
-$278M |
| 2 |
BIT
BlackRock Institutional Trust
San Francisco,
California
|
-$242M |
| 3 |
BFA
BlackRock Fund Advisors
San Francisco,
California
|
-$219M |
| 4 |
JHIU
Janus Henderson Investors US
Denver,
Colorado
|
-$150M |
| 5 |
Ameriprise
Minneapolis,
Minnesota
|
-$65.2M |
JAZZ Hedge Fund Activity: Q1 2015 in Review
355 of the 3,770 institutional investors tracked by Wall St. Rank reported a position in Jazz Pharmaceuticals (JAZZ) for Q1 2015, worth a combined $9.07B — up 1.6% from $8.93B a quarter earlier.
Buyers outnumbered sellers: 54 funds opened new JAZZ positions and 52 closed out — a net gain of 2 holders — while 137 added to existing stakes and 123 trimmed.
The largest buyer was Bank of New York Mellon, adding an estimated $97.6M. The largest seller was Lone Pine Capital, cutting an estimated $278M.
- 355 institutional investors held Jazz Pharmaceuticals (JAZZ) as of Q1 2015, down from 358 in Q4 2014.
- Funds reported $9.07B of Jazz Pharmaceuticals stock for Q1 2015, up 1.6% quarter-over-quarter.
- 54 funds opened new Jazz Pharmaceuticals positions in Q1 2015 and 52 closed out, a net change of +2 holders.
- The largest Jazz Pharmaceuticals buyer in Q1 2015 was Bank of New York Mellon, an estimated $97.6M added.
- The largest Jazz Pharmaceuticals seller in Q1 2015 was Lone Pine Capital, an estimated $278M sold.
Based on aggregated 13F filings for Q1 2015.